{"id":2977,"date":"2026-08-26T12:08:19","date_gmt":"2026-08-26T11:08:19","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/en\/?post_type=product&p=2977"},"modified":"2026-08-26T12:08:54","modified_gmt":"2026-08-26T11:08:54","slug":"buy-tesamorelin-cjc-1295-ipamorelin-blend-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/en\/product\/buy-tesamorelin-cjc-1295-ipamorelin-blend-in-switzerland\/","title":{"rendered":"Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12MG)"},"content":{"rendered":"

What Is the Tesamorelin & CJC-1295 & Ipamorelin Blend?<\/h2>\n

The Tesamorelin & CJC-1295 & Ipamorelin Blend is a 12mg research peptide formulation combining three complementary growth hormone secretagogues: Tesamorelin (4mg), a full-length 44-amino acid GHRH(1-44) analog with N-terminal trans-3-hexenoyl modification for enhanced stability; CJC-1295 (4mg), a 29-amino acid GHRH analog also known as Modified GRF 1-29; and Ipamorelin (4mg), a highly selective synthetic pentapeptide ghrelin receptor agonist. For those looking to buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland<\/strong>, Core Peptides offers high-quality research-grade material for laboratory applications.<\/p>\n

This triple blend pairs two GHRH analogues with a selective ghrelin receptor agonist, studied for synergistic amplification of growth hormone release through dual pituitary receptor pathway activation. Tesamorelin is the only GHRH analogue with FDA approval (HIV-associated lipodystrophy, 2 mg\/day subcutaneous) and multiple positive human RCTs, giving it the strongest evidence base in this blend category. CJC-1295 (without DAC) has a half-life of roughly 30 minutes, preserving pulsatility, while CJC-1295 with DAC has a half-life of roughly 8 days and produces continuous GH elevation. Ipamorelin is the most specific and selective ghrelin receptor agonist known, activating GHS-R1a without significantly affecting cortisol, prolactin, or ACTH levels at research doses. This selectivity distinguishes the Tesamorelin\/CJC-1295\/Ipamorelin combination from blends using less selective GHRPs such as GHRP-6 or GHRP-2.<\/p>\n

Research Overview<\/h2>\n

The Tesamorelin & CJC-1295 & Ipamorelin Blend has attracted research interest as a triple-pathway approach to investigating growth hormone axis physiology. Tesamorelin is a synthetic 44-amino acid peptide corresponding to the full-length sequence of endogenous human growth hormone-releasing hormone (GHRH(1-44)). CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) that mimics and amplifies the signal to the pituitary gland to release growth hormone. Meanwhile, Ipamorelin is a pentapeptide categorized as a selective growth hormone secretagogue that interacts with ghrelin receptors in the anterior pituitary.<\/p>\n

Research interest in this blend centers on the synergistic interaction between these pathways. Tesamorelin and CJC-1295 act as GHRH receptor agonists, while Ipamorelin acts through a distinct GHS-R1a pathway. Because these two systems converge on GH release through different intracellular pathways, they produce synergistic (not merely additive) effects when activated simultaneously. Their distinct mechanisms of action may complement each other, potentially amplifying growth hormone release and its downstream impacts on cellular functions. Consequently, this triple blend has generated significant interest as a research tool for investigating growth hormone physiology, pituitary function, and the hypothalamic-pituitary-somatotroph axis.<\/p>\n

When researchers choose to buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland<\/strong> for laboratory studies, they gain access to a compound that may help elucidate mechanisms of synergistic GH secretion, dual GPCR signaling convergence, and growth hormone regulation at the molecular level.<\/p>\n

How Does the Triple Blend Work?<\/h2>\n

The Tesamorelin & CJC-1295 & Ipamorelin Blend exerts its biological effects through simultaneous activation of two distinct pituitary receptor pathways that converge on somatotroph cells to amplify growth hormone release.<\/p>\n

Tesamorelin and CJC-1295: GHRH Receptor Activation<\/h3>\n

Tesamorelin and CJC-1295 mimic endogenous GHRH by binding to the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs.<\/p>\n

CJC-1295 binds to GHRH receptors on the pituitary gland, stimulating the release of growth hormone in pulses that preserve the body’s natural GH rhythm. This class B GPCR activates the Gs\/adenylyl cyclase\/cAMP\/PKA cascade. PKA then phosphorylates L-type calcium channels and the CREB transcription factor. This simultaneously triggers acute GH release and stimulates GH gene transcription. Importantly, this preserves normal GH pulsatility and feedback regulation.<\/p>\n

Tesamorelin incorporates a critical structural modification: a trans-3-hexenoic acid group attached to the N-terminus. This hexenoyl cap shields the peptide from rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), roughly tripling its plasma persistence without altering its receptor binding profile. CJC-1295 without DAC (Modified GRF 1-29) has a half-life of roughly 30 minutes, preserving pulsatility, while CJC-1295 with DAC has a half-life of roughly 8 days.<\/p>\n

Ipamorelin: Ghrelin Receptor Activation<\/h3>\n

Ipamorelin acts as an agonist of the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R1a). This Gq-coupled receptor activates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes endoplasmic reticulum calcium stores, releasing Ca\u00b2\u207a into the cytoplasm. Meanwhile, DAG activates protein kinase C (PKC), which interacts with protein synthesis related to GH synthesis.<\/p>\n

Ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. Unlike earlier compounds in its category, Ipamorelin appears to display a more targeted interaction profile, minimizing engagement with other endocrine pathways. Research indicates that Ipamorelin may stimulate growth hormone release through a mechanism distinct from GHRH analogs, thereby offering a complementary signaling route. Ipamorelin is more selective, raising GH without elevating adrenocorticotropic hormone (ACTH)\/cortisol.<\/p>\n

Synergistic Amplification<\/h3>\n

The triple blend exploits dual signaling convergence on somatotroph calcium levels. Tesamorelin- and CJC-1295-mediated cAMP\/PKA signaling sensitizes voltage-gated calcium channels. At the same time, Ipamorelin-mediated IP\u2083\/PKC signaling mobilizes intracellular calcium. The convergent activation of these distinct receptor systems on the same somatotroph cell produces synergistic GH pulse amplification.<\/p>\n

When researchers administer these peptides together, they stimulate the pituitary gland through multiple pathways, resulting in a significantly amplified and more sustained release of growth hormone compared to any single peptide alone. Importantly, this triple mechanism preserves the physiological pulsatile pattern of GH release and maintains negative feedback via IGF-1 and somatostatin, distinguishing it from exogenous GH administration. Rather than producing a linear increase in hormone levels, the blend supports a pattern that more closely resembles endogenous secretion cycles.<\/p>\n

Researchers who buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland<\/strong> for research purposes can investigate these mechanisms across diverse experimental models of growth hormone physiology and pituitary function.<\/p>\n

Why Is This Triple Blend Studied?<\/h2>\n

Researchers study the Tesamorelin & CJC-1295 & Ipamorelin Blend primarily for its potential relevance to growth hormone physiology, pituitary function, and the hypothalamic-pituitary-somatotroph axis. The synergistic amplification of GH release through complementary pathways makes it a valuable tool for understanding the molecular basis of GH regulation.<\/p>\n

Tesamorelin has been extensively studied in the context of metabolic research, particularly for its effects on visceral adipose tissue. In HIV-infected patients with lipodystrophy, Tesamorelin has demonstrated efficacy in reducing visceral adipose tissue (VAT) and improving body composition. Tesamorelin is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. Research has also explored its effects on hepatic fat, lean body mass, and IGF-1 levels.<\/p>\n

CJC-1295 has demonstrated dose-dependent, sustained increases in both GH and IGF-1 levels in healthy adults, with no observed desensitization of the pituitary gland over time. Elevated GH levels increase lipolysis (fat breakdown) while preserving lean muscle mass.<\/p>\n

Moreover, researchers study Ipamorelin in the context of selective GH release without significant cortisol or prolactin elevation. Studies showed that ipamorelin was the first GHRP not to stimulate cortisol significantly. This selectivity makes Ipamorelin a valuable tool for investigating GH release pathways without confounding hormonal effects.<\/p>\n

Researchers who buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland<\/strong> from Core Peptides can incorporate this peptide into their studies on GHRH receptor signaling, ghrelin receptor pharmacology, somatotroph function, and growth hormone physiology.<\/p>\n

Research Areas<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nDescription<\/th>\n<\/tr>\n<\/thead>\n
Synergistic GH Release<\/strong><\/td>\nInvestigating the combined effects of GHRH analogs (Tesamorelin, CJC-1295) and Ipamorelin on GH secretion<\/td>\n<\/tr>\n
GHRH Receptor Pharmacology<\/strong><\/td>\nStudying Tesamorelin and CJC-1295 binding and activation of GHRH-R on somatotrophs<\/td>\n<\/tr>\n
Ghrelin Receptor (GHS-R1a) Studies<\/strong><\/td>\nExamining Ipamorelin’s selective activation of the ghrelin receptor<\/td>\n<\/tr>\n
cAMP\/PKA Signaling<\/strong><\/td>\nInvestigating the cAMP pathway activated by GHRH analogs<\/td>\n<\/tr>\n
PLC\/IP3\/DAG Pathway<\/strong><\/td>\nExploring the phospholipase C pathway activated by Ipamorelin<\/td>\n<\/tr>\n
Somatotroph Function<\/strong><\/td>\nStudying the effects of triple pathway activation on pituitary somatotroph cells<\/td>\n<\/tr>\n
Growth Hormone Physiology<\/strong><\/td>\nExploring pulsatile GH secretion and the hypothalamic-pituitary-somatotroph axis<\/td>\n<\/tr>\n
Metabolic Research<\/strong><\/td>\nInvestigating effects on visceral adipose tissue, lipid metabolism, and body composition<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Scientific Research<\/h2>\n

Researchers have conducted scientific studies on Tesamorelin, CJC-1295, Ipamorelin, and their combinations in both in vitro and in vivo settings. They have derived evidence from cell cultures, preclinical models, and clinical research.<\/p>\n

Tesamorelin Evidence<\/h3>\n

Tesamorelin has been extensively studied in human clinical research. The FDA initially approved Tesamorelin (Egrifta) in November 2010 for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. In HIV-associated lipodystrophy, a meta-analysis of four randomized controlled trials (909 patients) demonstrated that Tesamorelin 2mg significantly reduced visceral adipose tissue.<\/p>\n

In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF. Tesamorelin is the only GHRH analogue with an FDA approval and multiple positive human RCTs, giving it the strongest evidence base in this stack category.<\/p>\n

CJC-1295 Evidence<\/h3>\n

CJC-1295 has been studied in human clinical trials, including studies in The Journal of Clinical Endocrinology and Metabolism, demonstrating that even low weekly doses of CJC-1295 produce dose-dependent, sustained increases in both GH and IGF-1 levels in healthy adults. Published Phase 1 and Phase 2 human trials have confirmed these findings.<\/p>\n

One study identified CJC-1295 as a stable and active hGRF1-29 analog with an extended plasma half-life. CJC-1295 without DAC (also called Modified GRF 1-29) has a shorter half-life than the DAC-conjugated version in the blood.<\/p>\n

Ipamorelin Evidence<\/h3>\n

Ipamorelin has been characterized as the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. A pharmacological profiling using GHRP and GHRH antagonists clearly demonstrated that ipamorelin stimulates GH release via a GHRP-like receptor. Early studies showed that ipamorelin was the first GHRP not to stimulate cortisol significantly.<\/p>\n

Nevertheless, researchers should note that Ipamorelin’s synergy with GHRH analogues is supported by animal and mechanistic data but has not been confirmed in a published human RCT as a combination. This blend is supplied for laboratory research purposes only. Scientists who buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland<\/strong> should remain aware of these evidence considerations.<\/p>\n

Compared With Related Peptides<\/h2>\n\n\n\n\n\n\n\n\n\n
Peptide\/Blend<\/th>\nRelationship<\/th>\nKey Differences<\/th>\n<\/tr>\n<\/thead>\n
Tesamorelin Alone<\/strong><\/td>\nSingle component of the blend<\/td>\nTesamorelin alone activates only GHRH-R; the blend adds CJC-1295 and Ipamorelin for synergistic amplification<\/td>\n<\/tr>\n
CJC-1295 Alone<\/strong><\/td>\nSingle component of the blend<\/td>\nCJC-1295 alone activates only GHRH-R; the blend adds Tesamorelin and Ipamorelin<\/td>\n<\/tr>\n
Ipamorelin Alone<\/strong><\/td>\nSingle component of the blend<\/td>\nIpamorelin alone activates only GHS-R1a; the blend adds two GHRH analogs for synergistic amplification<\/td>\n<\/tr>\n
Sermorelin & GHRP-2 Blend<\/strong><\/td>\nBoth are GHRH + GHRP blends<\/td>\nGHRP-2 is less selective; Ipamorelin is highly selective with minimal off-target effects; Tesamorelin is FDA-approved<\/td>\n<\/tr>\n
Growth Hormone (GH)<\/strong><\/td>\nBlend stimulates endogenous GH<\/td>\nGH is direct exogenous administration; the blend stimulates natural pulsatile GH release<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Research Applications<\/h2>\n

Researchers utilize the Tesamorelin & CJC-1295 & Ipamorelin Blend in a variety of laboratory research applications, primarily in the fields of endocrinology, receptor pharmacology, and growth hormone physiology. Key research applications include:<\/p>\n